Clinical Trial Update: Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1a/1b clinical trial evaluating TILT-123 (oncolytic adenovirus) with pembrolizumab, and with pegylated liposomal doxorubicin, for platinum-refractory/re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)
• Pembrolizumab (pembrolizumab)
• TILT-123 (tilt-123)

Snippet

Sponsor: TILT Biotherapeutics Ltd. | Conditions: Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer | Phase 1, Phase 2 | Status: RECRUITING